Phospho-ITGB1 (T789) Antibody

What is ITGB1 T789 phosphorylation and its biological significance?

ITGB1 (Integrin beta 1) can undergo phosphorylation at threonine 789, which is located in its cytoplasmic tail region. This post-translational modification has been hypothesized to regulate integrin activation, signaling, and cellular functions including adhesion and migration. The phosphorylation site is surrounded by the amino acid sequence V-T-T(P)-V-V . When paired with various alpha integrins, ITGB1 forms functional heterodimers that serve as receptors for extracellular matrix proteins including collagen, fibronectin, and fibrinogen . The phosphorylation at T789 is thought to potentially regulate these interactions, although recent research has raised questions about the detectability and prevalence of this modification in certain experimental contexts .

What applications are Phospho-ITGB1 (T789) antibodies typically used for?

Phospho-ITGB1 (T789) antibodies are employed in multiple experimental applications to detect and quantify phosphorylated ITGB1. The most common applications include:

• Western blotting (WB): For detecting phosphorylated ITGB1 in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing phosphorylated ITGB1 in tissue sections

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization of phosphorylated ITGB1

• ELISA: For quantitative measurement of phosphorylated ITGB1 levels

Recommended dilutions for these applications vary by manufacturer but typically range from 1:50-1:100 for IHC, 1:100-1:500 for IF/ICC, and 1:500-1:3000 for Western blotting .

How should researchers store and handle Phospho-ITGB1 (T789) antibodies?

For optimal performance and longevity of Phospho-ITGB1 (T789) antibodies, researchers should follow these handling guidelines:

• Long-term storage: Store at -20°C for up to one year

• Short-term/frequent use: Store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles which can degrade antibody quality

• Store in aliquots rather than repeatedly freezing and thawing the entire stock

• Most commercial antibodies are supplied in PBS (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150 mM NaCl, 0.02% sodium azide, and 50% glycerol

How can researchers validate the specificity of Phospho-ITGB1 (T789) antibodies?

Recent research has highlighted significant concerns regarding the specificity of commercial Phospho-ITGB1 (T789) antibodies. To validate specificity, researchers should consider implementing the following approaches:

• Peptide competition assays: Pre-incubate the antibody with a synthetic phosphopeptide corresponding to the T789 region before application to samples. This should abolish specific binding signals .

• Use of phosphorylation-deficient controls: Compare signals between wild-type cells and those expressing non-phosphorylatable ITGB1 mutants (e.g., T789A) .

• Immunoprecipitation followed by Western blotting: Immunoprecipitate ITGB1 with a well-validated antibody against the total protein, then probe for phosphorylation using the phospho-specific antibody .

• Mass spectrometry validation: Use MS/MS to confirm the presence of phosphorylated peptides in samples showing positive immunoreactivity .

Recent research has demonstrated that some commercial antibodies may detect proteins unrelated to ITGB1, producing signals of approximately 125-130 kD in both wild-type and ITGB1 knockout cells .

What evidence exists about potential cross-reactivity of Phospho-ITGB1 (T789) antibodies?

Recent studies have raised significant concerns about the specificity of commercial Phospho-ITGB1 (T789) antibodies. Key findings include:

• Antibodies from multiple commercial sources detected proteins of 125-130 kD (corresponding to mature ITGB1's apparent molecular weight) in both wild-type cells and ITGB1 knockout fibroblasts, suggesting recognition of unrelated proteins .

• Signals of similar size and kinetics were detected in cells expressing non-phosphorylatable ITGB1-TT788/789AA mutants, further indicating potential cross-reactivity .

• The 125-130 kD signal detected in whole cell lysates was undetectable in ITGB1 immunoprecipitates, suggesting the antibodies might not be recognizing phosphorylated ITGB1 .

• In immunofluorescence experiments, some anti-β1-pTpT antibodies produced signals at filopodia tips and along actin fibers in both wild-type and knockout cells .

These findings suggest researchers should exercise caution when interpreting results obtained with these antibodies and implement appropriate controls.

How can mass spectrometry complement antibody-based detection of phosphorylated ITGB1?

Mass spectrometry (MS) offers a complementary, antibody-independent approach for detecting and quantifying ITGB1 phosphorylation. Implementation strategies include:

• Sample preparation: Immunoprecipitate ITGB1 using antibodies against non-phosphorylated epitopes, followed by tryptic digestion and phosphopeptide enrichment.

• Targeted MS approaches: Use multiple reaction monitoring (MRM) or parallel reaction monitoring (PRM) to specifically detect the T789-containing phosphopeptide.

• Quantitative analysis: Use isotopically labeled synthetic phosphopeptides as internal standards for absolute quantification.

What experimental conditions might affect ITGB1 T789 phosphorylation?

Several factors have been investigated for their potential to induce or regulate ITGB1 T789 phosphorylation:

• Cell adhesion status: Changes in β1-tail phosphorylation have been reported during cell spreading on extracellular matrix proteins like fibronectin .

• Cell cycle stage: Mitotic arrest has been associated with changes in ITGB1 phosphorylation in some studies .

• Calcium signaling: Some researchers have used Ca²⁺ treatment of cells like HepG2 to potentially induce phosphorylation for antibody validation .

• PMA treatment: Phorbol esters have been used to stimulate protein kinase C activity, which might affect ITGB1 phosphorylation .

• Phosphatase inhibition: PPM1F phosphatase has been suggested to regulate ITGB1 phosphorylation, though experiments with PPM1F knockout cells did not show detectable differences in T789 phosphorylation levels .

How should researchers design appropriate controls for Phospho-ITGB1 (T789) antibody experiments?

Based on recent findings questioning antibody specificity, robust experimental controls are essential:

Recent evidence suggests that commercial antibodies may recognize unrelated proteins that produce signals similar in size and kinetics to ITGB1 , making these controls particularly important.

What methods can be used to induce and detect ITGB1 T789 phosphorylation?

Several approaches have been attempted to modulate and detect ITGB1 T789 phosphorylation:

• Substrate adhesion: Seeding cells on fibronectin has been used to potentially induce integrin activation and phosphorylation .

• Mitotic arrest: Stalling cells in mitosis using agents like nocodazole has been explored to potentially enhance phosphorylation .

• Kinase activation: Stimulation of potential upstream kinases including protein kinase C may influence ITGB1 phosphorylation .

• Detection methods beyond antibodies:

  • Metabolic labeling with ³²P

  • Phos-tag SDS-PAGE for mobility shift detection

  • Targeted mass spectrometry

  • Phosphorylation-specific protein interaction assays

How should researchers interpret contradictory results regarding ITGB1 T789 phosphorylation?

Recent literature reveals contradictions regarding the detection of ITGB1 T789 phosphorylation. When faced with such discrepancies, researchers should:

• Evaluate antibody validation methods: Recent studies found that some commercial anti-β1-pTpT antibodies showed immunoreactivity in both wild-type and ITGB1 knockout cells, suggesting non-specific binding .

• Consider detection limits: The phosphorylation may exist at levels below detection thresholds of conventional methods or occur only in specific subcellular compartments .

• Assess technical variability: Different lysis conditions, buffer compositions, or detection methods may affect the preservation and detection of the phosphorylation.

• Examine biological context: The phosphorylation may be cell-type specific, transient, or regulated by specific signaling pathways.

• Cross-validate using multiple methods: Combine antibody-based detection with orthogonal approaches like mass spectrometry or metabolic labeling.

Research has found that even when using mass spectrometry to analyze ITGB1 immunoprecipitates from various conditions, phosphorylated β1-T788/T789 peptides were not detected despite clear identification of the non-phosphorylated peptide .

What are common pitfalls in Western blotting with Phospho-ITGB1 (T789) antibodies?

Several challenges have been documented when using Phospho-ITGB1 (T789) antibodies for Western blotting:

• Non-specific bands: Recent research observed that commercial antibodies detected proteins of 125-130 kD in ITGB1 knockout cells, suggesting cross-reactivity with unrelated proteins .

• Signal absence in ITGB1 immunoprecipitates: In some studies, signals detected in whole cell lysates were absent when probing ITGB1 immunoprecipitates, suggesting the antibodies might not be detecting phosphorylated ITGB1 .

• Sample preparation effects: Phosphorylation may be lost during sample preparation due to phosphatase activity.

To address these issues, researchers should:

• Include appropriate controls (ITGB1 knockout cells, phosphorylation-deficient mutants)

• Use phosphatase inhibitors during sample preparation

• Consider using Phos-tag SDS-PAGE to enhance separation of phosphorylated proteins

• Validate results using multiple antibodies from different sources

• Complement antibody-based detection with mass spectrometry

What factors affect the reproducibility of Phospho-ITGB1 (T789) antibody experiments?

Several factors can influence the reproducibility of experiments using Phospho-ITGB1 (T789) antibodies:

• Antibody batch variation: Different lots may have varying specificity and sensitivity profiles.

• Cell context: The detection of phosphorylation may depend on cell type, culture conditions, and activation state.

• Technical variables: Fixation methods, blocking agents, and detection systems can all affect signal-to-noise ratios.

• Phosphorylation dynamics: ITGB1 T789 phosphorylation may be transient and regulated by multiple kinases and phosphatases.

• Antibody specificity issues: Recent research has raised concerns about whether commercial antibodies truly detect phosphorylated ITGB1 or cross-react with other proteins .

To enhance reproducibility, researchers should standardize protocols, use appropriate controls, and validate findings with multiple detection methods.

How can researchers investigate the functional implications of ITGB1 T789 phosphorylation?

To explore the functional significance of ITGB1 T789 phosphorylation, researchers might employ these approaches:

• Phosphomimetic and phosphodeficient mutants: Generate T789D/E (phosphomimetic) and T789A (phosphodeficient) ITGB1 mutants and express them in ITGB1-null backgrounds to assess effects on:

  • Cell adhesion strength and dynamics

  • Migration rate and directionality

  • Integrin activation state (using conformation-specific antibodies)

  • Downstream signaling (FAK, Src activation)

  • Protein-protein interactions (talin, kindlin binding)

• Temporal dynamics: Use optogenetic or chemically-inducible kinase systems to temporally control phosphorylation and monitor acute cellular responses.

• Spatial regulation: Employ FRET-based biosensors to monitor phosphorylation in specific subcellular locations during cellular processes.

• Physiological relevance: Investigate phosphorylation status during development, tissue regeneration, or disease progression using phospho-specific antibodies (with appropriate controls) or mass spectrometry.

Importantly, recent research has questioned whether ITGB1 T789 phosphorylation occurs at detectable levels in multiple cell types , suggesting researchers should validate the presence of this modification in their specific system before attempting functional studies.

What recent advancements have been made in studying ITGB1 phosphorylation dynamics?

Recent research has produced important insights into ITGB1 phosphorylation:

• Antibody specificity concerns: Studies have raised significant questions about the specificity of commercial phospho-T788/T789 antibodies, finding that they may recognize proteins unrelated to ITGB1 .

• Detection challenges: Mass spectrometry analysis failed to detect phosphorylated β1-T788/T789 peptides in ITGB1 immunoprecipitates from various cellular conditions, while readily detecting the non-phosphorylated peptide .

• Cell-type investigations: Analysis across multiple cell types (fibroblasts, epithelial cells, macrophages, leukemia cells) has suggested that β1-T788/T789 phosphorylation may be below detection limits or absent under standard experimental conditions .

• Phosphatase regulation: Studies with PPM1F phosphatase knockout cells did not reveal detectable differences in T789 phosphorylation levels, challenging previous models of phosphorylation regulation .

These findings suggest a need to reassess models of ITGB1 phosphorylation and develop more sensitive or specific detection methods to clarify its biological significance.

How does ITGB1 T789 phosphorylation relate to other post-translational modifications of integrins?

ITGB1 undergoes multiple post-translational modifications that may interact with T789 phosphorylation:

• Additional phosphorylation sites: ITGB1 can be phosphorylated at other residues including Y783, S785, and T788, potentially creating complex phosphorylation patterns with distinct functional outcomes.

• Glycosylation: ITGB1 contains multiple N-glycosylation sites that affect protein folding, trafficking, and ligand binding. The interplay between glycosylation and phosphorylation remains poorly understood.

• Ubiquitination: Regulates ITGB1 degradation and internalization, potentially affected by phosphorylation status.

• Palmitoylation: Affects ITGB1 membrane distribution and signaling properties.

• Proteolytic processing: ITGB1 can undergo proteolytic cleavage events that may be influenced by phosphorylation.

What are best practices for immunohistochemistry with Phospho-ITGB1 (T789) antibodies?

When performing immunohistochemistry with Phospho-ITGB1 (T789) antibodies, researchers should consider these methodological approaches:

• Antibody validation: Use peptide competition assays with both phosphorylated and non-phosphorylated peptides to confirm specificity .

• Sample preparation: Optimize fixation protocols (typically formalin/PFA-fixed paraffin-embedded sections) to preserve phospho-epitopes .

• Antigen retrieval: Test different methods (heat-induced vs. enzymatic) to maximize epitope accessibility.

• Signal amplification: Consider using tyramide signal amplification for detecting low-abundance phosphorylation.

• Controls: Include tissue from ITGB1 knockout models or tissues treated with lambda phosphatase as negative controls.

• Dilution optimization: Recommended dilutions typically range from 1:50-1:100, but should be optimized for each application .

• Counterstaining: Use markers for specific cellular compartments to determine the subcellular localization of phosphorylated ITGB1.

Images from antibody validation show that blocking peptide treatment can effectively eliminate specific staining in human breast cancer tissue sections when using Phospho-ITGB1 (T789) antibodies .

How can researchers quantify ITGB1 T789 phosphorylation levels accurately?

Accurate quantification of ITGB1 T789 phosphorylation requires careful methodological considerations:

• Western blot quantification:

  • Always normalize phospho-ITGB1 signal to total ITGB1 levels

  • Use recombinant phosphorylated standards for calibration

  • Ensure linearity of detection system across the dynamic range of measurement

  • Include phosphatase-treated controls to establish baseline

• ELISA-based approaches:

  • Develop sandwich ELISAs using capture antibodies against total ITGB1 and detection antibodies against phospho-T789

  • Include standard curves with synthetic phosphopeptides

  • Validate using samples with known phosphorylation status

• Mass spectrometry-based quantification:

  • Use stable isotope-labeled synthetic phosphopeptides as internal standards

  • Consider AQUA (absolute quantification) methodology

  • Account for potential suppression effects in complex samples

  • Combine with phosphopeptide enrichment strategies

Researchers should note that recent studies have raised concerns about the specificity of commercial Phospho-ITGB1 (T789) antibodies and the detectability of this phosphorylation in various cell types , suggesting that quantification results should be interpreted cautiously and validated using multiple approaches.

What specialized techniques can enhance detection of ITGB1 T789 phosphorylation in challenging samples?

For samples where standard methods fail to detect ITGB1 T789 phosphorylation, specialized approaches may help:

• Phosphopeptide enrichment: Use TiO₂, IMAC, or phospho-specific antibodies to enrich phosphopeptides before mass spectrometry analysis.

• Phos-tag SDS-PAGE: This technique specifically retards the migration of phosphorylated proteins, allowing separation of phosphorylated and non-phosphorylated ITGB1.

• Proximity ligation assay (PLA): Combine antibodies against total ITGB1 and phospho-T789 to generate signals only when the epitopes are in close proximity.

• Nano-flow LC-MS/MS: Increases sensitivity for detection of low-abundance phosphopeptides.

• ELISA with signal amplification: Employ tyramide signal amplification or poly-HRP systems to enhance detection of low-level phosphorylation.

• Phosphatase inhibitor cocktails: Use optimized combinations during sample preparation to prevent loss of phosphorylation.

Despite employing sophisticated methods including immunoprecipitation followed by mass spectrometry, recent research has reported difficulties detecting ITGB1 T789 phosphorylation in multiple cell types , suggesting this modification may be extremely low abundance, transient, or present only under specific conditions not yet identified.

What are the most significant unresolved questions regarding ITGB1 T789 phosphorylation?

Despite years of research, several critical questions about ITGB1 T789 phosphorylation remain unanswered:

• Is the phosphorylation truly occurring in physiological contexts? Recent research has raised substantial questions about whether T789 phosphorylation occurs at detectable levels in multiple cell types under various conditions .

• What is the stoichiometry of phosphorylation? If the modification occurs, what percentage of ITGB1 molecules are phosphorylated at a given time?

• Which kinases and phosphatases directly regulate T789 phosphorylation in vivo?

• What are the precise spatiotemporal dynamics of T789 phosphorylation during processes like cell adhesion, migration, and division?

• How does T789 phosphorylation affect ITGB1 conformation, interactions with cytoskeletal and signaling proteins, and downstream signaling cascades?

• What is the evolutionary conservation of this phosphorylation site and its regulatory mechanisms across species?

Addressing these questions will require developing more sensitive and specific detection methods, as well as sophisticated cellular and in vivo models.

How might emerging technologies improve our understanding of ITGB1 phosphorylation?

Several emerging technologies hold promise for advancing research on ITGB1 T789 phosphorylation:

• Highly sensitive mass spectrometry: New instruments with improved sensitivity may detect low-abundance phosphorylation events previously below detection thresholds.

• Genetically encoded biosensors: FRET-based or intensiometric sensors could enable real-time visualization of phosphorylation dynamics in living cells.

• Proximity labeling proteomics: BioID or APEX2 fused to phospho-specific binding domains could identify proteins that interact specifically with phosphorylated ITGB1.

• Single-molecule imaging: Super-resolution microscopy combined with phospho-specific probes might reveal nanoscale organization of phosphorylated integrins.

• CRISPR-based precise genome editing: Introduction of specific phosphorylation site mutations in endogenous genes could help assess functional consequences in physiological contexts.

• Synthetic phosphoproteomics: Chemical genetics approaches using engineered kinases might help identify direct substrates and phosphorylation dynamics.

These approaches could help resolve current contradictions in the literature and provide more definitive answers about the occurrence and significance of ITGB1 T789 phosphorylation.

What implications do recent findings have for therapeutic approaches targeting integrin signaling?

Recent findings questioning the specificity of Phospho-ITGB1 (T789) antibodies and the detectability of this phosphorylation have several implications for therapeutic strategies:

• Target validation concerns: If T789 phosphorylation is rare or absent in physiological contexts, therapeutic approaches targeting this modification or its regulatory machinery may lack efficacy.

• Biomarker reliability: The use of phosphorylated ITGB1 as a biomarker for disease states or treatment responses requires reassessment given questions about antibody specificity.

• Alternative approaches: Rather than targeting specific phosphorylation events, broader strategies affecting integrin activation, clustering, or trafficking might prove more effective.

• Diagnostic tool development: More reliable methods for detecting ITGB1 phosphorylation status could improve patient stratification for integrin-targeted therapies.

• Pathway redundancy: The apparent absence or low abundance of T789 phosphorylation suggests potential redundancy in integrin regulation, highlighting the need for combinatorial therapeutic approaches.